EverSource Wealth Advisors LLC Acquires 1,770 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

EverSource Wealth Advisors LLC boosted its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 51.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,190 shares of the company’s stock after buying an additional 1,770 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Takeda Pharmaceutical were worth $69,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in TAK. Versant Capital Management Inc purchased a new position in Takeda Pharmaceutical during the fourth quarter valued at approximately $26,000. Wilmington Savings Fund Society FSB purchased a new position in Takeda Pharmaceutical during the third quarter valued at approximately $40,000. BNP Paribas Financial Markets lifted its holdings in Takeda Pharmaceutical by 416.0% during the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after purchasing an additional 2,596 shares in the last quarter. Smithfield Trust Co lifted its holdings in Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock valued at $49,000 after purchasing an additional 1,490 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in Takeda Pharmaceutical during the third quarter valued at approximately $52,000. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $15.14 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.24. The company has a market capitalization of $48.16 billion, a P/E ratio of 37.84, a P/E/G ratio of 0.24 and a beta of 0.46. The firm’s 50 day simple moving average is $13.87 and its two-hundred day simple moving average is $13.91.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.